Pharvaris 1 article

The therapeutic identity of Pharvaris combines hereditary angioedema therapeutics and bradykinin B2 receptor antagonism; the organization operates as a biopharmaceutical company. Pharvaris combines acute angioedema therapeutics, prophylactic angioedema therapeutics and B2 receptor selective inhibition, giving Pharvaris an explicit target or pathway context. This framing preserves Pharvaris as the company entity, with vascular permeability modulation contributing context without collapsing products, targets and modalities together.